Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Number 5: Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia ...